Ip3 Receptor 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Inositol 1,4,5-trisphosphate receptor type 1 (IP₃R1) is a ligand-gated calcium release channel located primarily on the endoplasmic reticulum (ER) membrane. It functions as the primary receptor for IP₃, a second messenger generated by phospholipase C (PLC) activation. Upon IP₃ binding, IP₃R1 opens to allow calcium release from ER stores into the cytoplasm, initiating a wide range of cellular processes including muscle contraction, secretion, gene transcription, and neuronal signaling. IP₃R1 is particularly abundant in cerebellar Purkinje neurons and plays essential roles in synaptic plasticity, learning, and memory. Dysregulation of IP₃R1 function is implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and spinocerebellar ataxias.
| IP3 Receptor 1 Protein | |
|---|---|
| Protein Name | IP3 Receptor 1 Protein |
| Gene | ITPR1 |
| UniProt ID | Q14643 |
| PDB IDs | 3T1S, 4J6N, 5D5M |
| Molecular Weight | 313 kDa |
| Subcellular Location | Endoplasmic reticulum membrane |
| Protein Family | IP3 receptor family |
IP3 Receptor 1 Protein is a IP3 receptor family. This protein contains characteristic transmembrane domains and regulatory domains that control channel activity and calcium release.
ITPR1 (IP3R1) is an intracellular calcium release channel on the endoplasmic reticulum. It releases calcium in response to IP3 binding, generating calcium signals that regulate synaptic plasticity, gene expression, and cellular metabolism. IP3R1 is highly expressed in cerebellar Purkinje cells and hippocampal neurons. It forms tetramers and is regulated by calcium, ATP, and various kinases/phosphatases.
ITPR1 mutations cause spinocerebellar ataxia (SCA15/SCA29) and cerebellar degeneration. ITPR1 dysfunction is implicated in AD (altered calcium release), PD, and Huntington's disease. Reduced IP3R1 expression is observed in AD brains.
No specific ITPR1-targeted drugs are approved. Tetrabenazine and related compounds modulate IP3R indirectly. Gene therapy approaches are being explored for SCA.
The study of Ip3 Receptor 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.